JPRN-jRCT1090220279CompletedUnknown
Study for serum total cholesterol-lowering action of egg white protein containing beverage - Egg white cholesterol study
Trial Snapshot
- Phase
- Unknown
- Status
- Completed
- Sponsor
- Kewpie Corporation
- Enrollment
- 88
Study Overview
Brief Summary
E may be effective in helping to prevent arteriosclerotic diseases.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- >= 20age old to < 65age old (—)
- Sex
- Male
Inclusion Criteria
- •(1) Japanese males with mild hypercholesterolemia of at least 20 years and not more than 65 years of age, (2) not undergoing treatment for hyperlipidemia, (3) not undergoing treatment for diabetes, (4) had no subjective symptoms of gout, (5) capable of filling out necessary forms such as self-diagnosis forms, and (6) capable of visiting a designated institution as scheduled.
Exclusion Criteria
- •(1) those who were taking drugs considered to potentially affect test results (e.g., anti-hyperlipidemic agents, anti-diabetic agents, oral corticosteroid formulations, and antihypertensive agents), (2) were regularly consuming foods for specified health uses considered to potentially affect test results, (3) were excessively consuming alcohol, (4) suspected to develop allergic reactions (particularly those allergic to egg and milk), (5) those who were participating in other clinical studies, (6) had a history of serious liver damage, kidney damage, or myocardial infarction, (7) had a history of or currently had hepatitis, and (8) had serious anemia. The candidates who fulfilled the abovementioned criteria then underwent a screening survey.
Investigators
Similar Trials
Completed
Phase 3
Lipid Research Clinics Coronary Primary Prevention Trial (CPPT)Cardiovascular DiseasesCoronary DiseaseHeart DiseasesMyocardial IschemiaNCT00000488National Heart, Lung, and Blood Institute (NHLBI)
Completed
Phase 3
Program on Surgical Control of Hyperlipidemias (POSCH)Cardiovascular DiseasesCoronary DiseaseHeart DiseasesMyocardial InfarctionMyocardial IschemiaNCT00000490University of Minnesota
Terminated
Phase 2
Eliminate Coronary Artery DiseaseCoronary Artery DiseaseNCT02245087University Health Network, Toronto28
Completed
Phase 4
A Study to Determine the Degree of Additional Reduction in CV Risk in Lowering LDL Below Minimum Target LevelsCardiovascular DiseaseCerebrovascular AccidentCoronary Heart DiseaseNCT00327691Pfizer8,600
Recruiting
Not Applicable
Study for evaluation of cholesterol lowering effect, dose and safety of Bifidobacterium breve IDCC 4401KCT0003040Ildong pharmaceutical66